Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis

Zhu, Bing; Qie, Yaqing; Wang, Jiu ling; Zhang, Ying; Wang, Qing zhong; Xu, Ying; Wang, Honghai

doi:10.1016/j.ejpb.2006.11.028

Cited by 47 publications

(24 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although CS has shown potential therapeutic activity as anti-microbial (22), wound healing (23), hypo-cholesterolemic (24) and anti-ulcer agent (20), its potential application still lies in formulating drug delivery systems (16,17,25,26). In the past decades, CS has been extensively used for delivery of small molecules (6,27), peptides (25), vaccines (28,29) and genes (30,31) via mucosal (29,(32)(33)(34), nasal (25,(35)(36)(37)(38)(39), colon (40), topical (41), oral (4,15) or parenteral route (20,25,(42)(43)(44)(45)(46)(47). However, its chemical versatility to form derivatives or cross-links (4,13,29), mucoadhesive property (4,(48)(49)(50)(51), permeation-enhancing capability (4,49,<...>…”

Section: Introductionmentioning

confidence: 99%

Recent Advancement of Chitosan-Based Nanoparticles for Oral Controlled Delivery of Insulin and Other Therapeutic Agents

2010

View full text Add to dashboard Cite

Abstract. Nanoparticles composed of naturally occurring biodegradable polymers have emerged as potential carriers of various therapeutic agents for controlled drug delivery through the oral route. Chitosan, a cationic polysaccharide, is one of such biodegradable polymers, which has been extensively exploited for the preparation of nanoparticles for oral controlled delivery of several therapeutic agents. In recent years, the area of focus has shifted from chitosan to chitosan derivatized polymers for the preparation of oral nanoparticles due to its vastly improved properties, such as better drug retention capability, improved permeation, enhanced mucoadhesion and sustained release of therapeutic agents. Chitosan derivatized polymers are primarily the quaternized chitosan derivatives, chitosan cyclodextrin complexes, thiolated chitosan, pegylated chitosan and chitosan combined with other peptides. The current review focuses on the recent advancements in the field of oral controlled release via chitosan nanoparticles and discusses about its in vitro and in vivo implications.

show abstract

Section: Introductionmentioning

confidence: 99%

Recent Advancement of Chitosan-Based Nanoparticles for Oral Controlled Delivery of Insulin and Other Therapeutic Agents

2010

View full text Add to dashboard Cite

show abstract

“…Chitosan microspheres to deliver a fusion protein, Ag85B-MPT64-Mtb8.4 (AMM), from three Mycobacterium tuberculosis genes were prepared and C57BL/6 mice were immunized at weeks 1, 3 and 5 subcutaneously with the AMM-loaded chitosan microspheres (6 mm), with AMM in incomplete Freund's adjuvant (IFA), or with AMM in PBS [75]. Splenocytes immunized with AMM loaded chitosan microspheres were found to produce higher levels of IFN-g compared to that of control.…”

Section: Parenteral Deliverymentioning

confidence: 99%

Chitosan-Based Particulate Systems for Non-Invasive Vaccine Delivery

Şenel

2011

Advances in Polymer Science

View full text Add to dashboard Cite

The use of particulate systems is considered very promising for the delivery of antigenic molecules via parenteral and non-parenteral routes. They provide improved protection and facilitated transport of the antigen as well as more effective antigen recognition by the immune cells, which results in enhanced immune responses. The natural cationic polysaccharide chitosan has been investigated extensively both as an adjuvant and delivery system for vaccines. It has been shown to enhance both humoral and cellular responses. From the formulation point of view, chitosan-based particulate systems offer advantages over the other polymers used by avoiding the harsh conditions of heat and/or organic solvents for encapsulation of the antigen. Furthermore, versatility in the physicochemical properties of chitosan provides an exceptional opportunity to engineer antigen-specific adjuvant/delivery systems. In this review, the importance of chitosan in particulate systems for vaccine delivery will be emphasized according to administration routes, particularly focusing on non-invasive (needle-free) routes including oral, mucosal and pulmonary mucosae as well as skin.

show abstract

“…21,22 All of the injections were prepared under aseptic conditions under laminar air flow, and put into insulin syringes (31 gauge, 12.7 mm in length). The different groups of animals receiving the vaccine are summarized in Table 1.…”

Section: Evaluation Of Protein-loading In Nanoparticlesmentioning

confidence: 99%

Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice

Danesh-Bahreini¹,

Shokri²,

Samiei³

et al. 2011

IJN

View full text Add to dashboard Cite

Background: Leishmaniasis is a protozoan disease, affecting 12 million people in different regions of the world with a wide spectrum of diseases. Although several chemotherapeutic agents have been used for treating the disease, long-term therapy, limited efficacy and the development of drug-resistant parasites remain the major limitations. Methods: To develop a new nanovaccine for leishmaniasis, recombinant Leishmania superoxide dismutase (SODB1) was loaded onto chitosan nanoparticles by the ionotropic gelation method. Size and loading efficiency of the nanoparticles were evaluated and optimized, and an immunization study was undertaken on BALB/c mice. The mice received phosphate buffer saline (PBS), superoxide dismutase B1 (SODB1) in PBS and nanoparticles via subcutaneous injection. Soluble Leishmania Antigens (SLA) and complete Freund’s adjuvant (CFA) were also injected subcutaneously three times every three weeks (some groups received only a single dose). Three weeks after the last injection, blood samples were collected and assessed with ELISA to detect IgG2a and IgG1. Results: Immunological analysis showed that in single and triple doses of SODB1 nanoparticles, IgG2a and IgG2a/IgG1 were significantly higher than the other groups ( P <0.05). Conclusion: The results revealed that formulations of SODB1 in biodegradable and stable chitosan nanoparticles can increase the immunogenicity toward cell-mediated immunity (T H 1 cells producing IgG2a in mice) that is effective in Leishmania eradication and could be presented as a single dose nanovaccine for leishmaniasis.

show abstract

Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis

Cited by 47 publications

References 31 publications

Recent Advancement of Chitosan-Based Nanoparticles for Oral Controlled Delivery of Insulin and Other Therapeutic Agents

Recent Advancement of Chitosan-Based Nanoparticles for Oral Controlled Delivery of Insulin and Other Therapeutic Agents

Chitosan-Based Particulate Systems for Non-Invasive Vaccine Delivery

Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice

Contact Info

Product

Resources

About